Beena Rajagopal
Primary Care · Nashua, NHNPI 1700335791
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 283 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,700, more than ten times the $334 reported in 2023. Among primary care clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 283 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$976
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$886
- Takeda Pharmaceuticals U.S.A., Inc.$693
- Johnson & Johnson$670
- Gilead$454
- Pfizer$410
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,82798%
- Education$992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 58 | $976 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 65 | $886 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $693 |
| Johnson & Johnson | 27 | $670 |
| Gilead | 18 | $454 |
| Pfizer | 19 | $410 |
| Sanofi | 8 | $324 |
| Lilly USA, LLC | 8 | $260 |
| Regeneron Healthcare Solutions, Inc. | 10 | $208 |
| Ardelyx, Inc. | 8 | $134 |
| Intercept Pharmaceuticals, Inc. | 4 | $101 |
| Janssen Scientific Affairs, LLC | 1 | $96 |
| Alnylam Pharmaceuticals Inc. | 3 | $94 |
| Neuraxis, Inc. | 1 | $88 |
| Madrigal Pharmaceuticals | 2 | $87 |
| QOL Medical, LLC | 2 | $70 |
| Aimmune Therapeutics, Inc. | 3 | $70 |
| Ipsen Biopharmaceuticals, Inc | 2 | $49 |
| Ironwood Pharmaceuticals, Inc | 2 | $47 |
| Boehringer Ingelheim | 2 | $38 |
| Phathom Pharmaceuticals, Inc. | 1 | $30 |
| Bristol Myers Squibb | 1 | $27 |
| Ferring Pharmaceuticals Inc. | 1 | $23 |
| Celltrion USA Inc. | 1 | $20 |
| Novo Nordisk | 1 | $16 |
| Orphalan Inc | 1 | $15 |
| Braintree Laboratories, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Medtronic | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,926 in reported general payments places this provider in the 95th percentile of 31 primary care providers in New Hampshire.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 23 | $444 |
| Omeprazole | 33 | $412 |
| Famotidine | 20 | $409 |
| Topiramate | 11 | $87 |
| Metformin Hcl ErMetformin Hcl | 12 | $79 |
Paid to pharmacies, not to this prescriber.
Other primary care in Nashua
- Tina McGuirkNashua$760
- Alexandra Melo MarinezNashua$420
- Jean SchwartzLebanon$9K
- Kathleen DevejianHampstead$3K
- Kamila ZlotoschDurham$2K
- Deborah JensenHopkinton$801
- Jennifer TichichLaconia$709
- Melissa-Jo NasonConway$704
- Stephane CampagnaLittleton$680
- Emily GrattanSomersworth$647
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.